In this Article, members of the UCSF cohort who had been alive for longer than two years were inadvertently included in the data presented in Table 3. USCF/old treatments should have 109 patients with a hazard ratio of 3.35 and a P value of 0.00028 instead of the 124 patients with a hazard ratio of 3.37 and a P value of 0.00026. The USCF/new patients should have 187 patients with a hazard ratio of 3.57 and a P value of 0.0007 instead of the 208 patients with a hazard ratio of 3.62 and a P value of 0.0006. Finally, in the table legend, the first line should read ‘All models are adjusted for age, gender and principal components 1–3’. The exclusion of these individuals does not change the conclusions of the study. The correct version of Table 3 appears below.
Table 3. Effect of SNP by initial treatment among patients in the UCSF cohort.
| HR* | 95% CI | P value† | |
|---|---|---|---|
| Mayo Clinic | |||
| Old treatments‡ | N = 136, 102 deaths | ||
| RS72773978 | 1.90 | 0.98–3.83 | 0.057 |
| New treatments§ | N = 93, 64 deaths | ||
| RS72773978 | 2.71 | 1.56–4.70 | 0.00045 |
| Entire sample adjusted for treatment | N = 229, 166 deaths | ||
| RS72773978 | 2.18 | 1.43–3.32 | 0.00028 |
| UCSF | |||
| Old treatments‡ | N = 109 60 deaths | ||
| RS72773978 | 3.35 | 1.74–6.44 | 0.00028 |
| New treatments§ | N = 187, 30 deaths | ||
| RS72773978 | 3.57 | 1.71–7.43 | 0.0007 |
| Entire sample adjusted for treatment | N = 296, 90 deaths | ||
| RS72773978 | 3.35 | 2.07–5.41 | 8.2 x 10−7 |
All models are adjusted for age, gender and principal components 1-3.
P values are calculated from proportional hazards models.
Treatments containing at least one of the following agents: thalidomide, botezomib or lenalidomide.
Regimens including vincristine/adriamycin/dexamethasone or melphalan/prednisone.